The Clinician Interview-based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease

David S Knopman, Margaret J. Knapp, Stephen I. Gracon, Charles S. Davis

Research output: Contribution to journalArticle

202 Citations (Scopus)

Abstract

Global assessments are Food and Drug Administration-required primary outcome measures in trials of putative antidementia drugs. Global ratings are intended to provide an index of clinical importance of change that cannot be obtained from quantitative assessment measures such as mental status examinations. We examined the performance of a global assessment of change instrument, the Clinician Interview-Based Impression (CIBI), in the placebo group of a 30-week, randomized, double-blind clinical trial of tacrine in patients with Alzheimer's disease. Initially there were 184 placebo patients, of whom 125 completed the 30-week study. Descriptive statistics, correlations with changes on other assessment instruments, and test-retest reliability were determined for the CIBI. At week 30, clinicians rated more than 40% of patients on the CIBI as unchanged. The CIBI ratings were weakly but significantly correlated, in the expected direction, with change scores on the quantitative cognitive assessments. The CIBI was modestly reliable on test-retest at weeks 22 and 24 but less reliable compared with other quantitative outcome measures. Modifications of the CIBI that might improve its reliability and acceptance include (1) no restrictions on the form of the bedside mental status assessment, (2) inclusion of caregiver input, and (3) better definition of ratings on the global scale. Global instruments, if properly constructed, can provide an index of clinically important change for the assessment of dementia patients.

Original languageEnglish (US)
Pages (from-to)2315-2321
Number of pages7
JournalNeurology
Volume44
Issue number12
StatePublished - Dec 1994
Externally publishedYes

Fingerprint

Alzheimer Disease
Interviews
Placebos
Outcome Assessment (Health Care)
Tacrine
United States Food and Drug Administration
Reproducibility of Results
Caregivers
Dementia
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The Clinician Interview-based Impression (CIBI) : A clinician's global change rating scale in Alzheimer's disease. / Knopman, David S; Knapp, Margaret J.; Gracon, Stephen I.; Davis, Charles S.

In: Neurology, Vol. 44, No. 12, 12.1994, p. 2315-2321.

Research output: Contribution to journalArticle

Knopman, David S ; Knapp, Margaret J. ; Gracon, Stephen I. ; Davis, Charles S. / The Clinician Interview-based Impression (CIBI) : A clinician's global change rating scale in Alzheimer's disease. In: Neurology. 1994 ; Vol. 44, No. 12. pp. 2315-2321.
@article{8acee1f4994c41b59fa9a74f935cfcc2,
title = "The Clinician Interview-based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease",
abstract = "Global assessments are Food and Drug Administration-required primary outcome measures in trials of putative antidementia drugs. Global ratings are intended to provide an index of clinical importance of change that cannot be obtained from quantitative assessment measures such as mental status examinations. We examined the performance of a global assessment of change instrument, the Clinician Interview-Based Impression (CIBI), in the placebo group of a 30-week, randomized, double-blind clinical trial of tacrine in patients with Alzheimer's disease. Initially there were 184 placebo patients, of whom 125 completed the 30-week study. Descriptive statistics, correlations with changes on other assessment instruments, and test-retest reliability were determined for the CIBI. At week 30, clinicians rated more than 40{\%} of patients on the CIBI as unchanged. The CIBI ratings were weakly but significantly correlated, in the expected direction, with change scores on the quantitative cognitive assessments. The CIBI was modestly reliable on test-retest at weeks 22 and 24 but less reliable compared with other quantitative outcome measures. Modifications of the CIBI that might improve its reliability and acceptance include (1) no restrictions on the form of the bedside mental status assessment, (2) inclusion of caregiver input, and (3) better definition of ratings on the global scale. Global instruments, if properly constructed, can provide an index of clinically important change for the assessment of dementia patients.",
author = "Knopman, {David S} and Knapp, {Margaret J.} and Gracon, {Stephen I.} and Davis, {Charles S.}",
year = "1994",
month = "12",
language = "English (US)",
volume = "44",
pages = "2315--2321",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The Clinician Interview-based Impression (CIBI)

T2 - A clinician's global change rating scale in Alzheimer's disease

AU - Knopman, David S

AU - Knapp, Margaret J.

AU - Gracon, Stephen I.

AU - Davis, Charles S.

PY - 1994/12

Y1 - 1994/12

N2 - Global assessments are Food and Drug Administration-required primary outcome measures in trials of putative antidementia drugs. Global ratings are intended to provide an index of clinical importance of change that cannot be obtained from quantitative assessment measures such as mental status examinations. We examined the performance of a global assessment of change instrument, the Clinician Interview-Based Impression (CIBI), in the placebo group of a 30-week, randomized, double-blind clinical trial of tacrine in patients with Alzheimer's disease. Initially there were 184 placebo patients, of whom 125 completed the 30-week study. Descriptive statistics, correlations with changes on other assessment instruments, and test-retest reliability were determined for the CIBI. At week 30, clinicians rated more than 40% of patients on the CIBI as unchanged. The CIBI ratings were weakly but significantly correlated, in the expected direction, with change scores on the quantitative cognitive assessments. The CIBI was modestly reliable on test-retest at weeks 22 and 24 but less reliable compared with other quantitative outcome measures. Modifications of the CIBI that might improve its reliability and acceptance include (1) no restrictions on the form of the bedside mental status assessment, (2) inclusion of caregiver input, and (3) better definition of ratings on the global scale. Global instruments, if properly constructed, can provide an index of clinically important change for the assessment of dementia patients.

AB - Global assessments are Food and Drug Administration-required primary outcome measures in trials of putative antidementia drugs. Global ratings are intended to provide an index of clinical importance of change that cannot be obtained from quantitative assessment measures such as mental status examinations. We examined the performance of a global assessment of change instrument, the Clinician Interview-Based Impression (CIBI), in the placebo group of a 30-week, randomized, double-blind clinical trial of tacrine in patients with Alzheimer's disease. Initially there were 184 placebo patients, of whom 125 completed the 30-week study. Descriptive statistics, correlations with changes on other assessment instruments, and test-retest reliability were determined for the CIBI. At week 30, clinicians rated more than 40% of patients on the CIBI as unchanged. The CIBI ratings were weakly but significantly correlated, in the expected direction, with change scores on the quantitative cognitive assessments. The CIBI was modestly reliable on test-retest at weeks 22 and 24 but less reliable compared with other quantitative outcome measures. Modifications of the CIBI that might improve its reliability and acceptance include (1) no restrictions on the form of the bedside mental status assessment, (2) inclusion of caregiver input, and (3) better definition of ratings on the global scale. Global instruments, if properly constructed, can provide an index of clinically important change for the assessment of dementia patients.

UR - http://www.scopus.com/inward/record.url?scp=0028114429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028114429&partnerID=8YFLogxK

M3 - Article

C2 - 7991118

AN - SCOPUS:0028114429

VL - 44

SP - 2315

EP - 2321

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -